Epkinly/Tepkinly (Epcoritamab-bysp)

Epkinly/Tepkinly (epcoritamab-bysp) is a bispecific CD20-directed CD3 T-cell engager indicated:

• For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
  This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
• In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
• As monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Recommended Dosage:
The recommended dosage of Epkinly/Tepkinly is administered as a subcutaneous (SC) injection. Treatment is given in repeated cycles and should be continued until there is evidence of disease progression or unacceptable toxicity occurs, as determined by the treating physician.
For patients with diffuse large B-cell lymphoma, treatment typically starts with gradually increased introductory doses during the initial treatment period before moving to the standard maintenance dosing schedule. This step-up approach helps the body adjust to the therapy and reduces the risk of treatment-related reactions.

In follicular lymphoma, this medicine may be used as a single therapy or in combination with other medicines such as lenalidomide and rituximab. Similar to other indications, the treatment begins with carefully escalated introductory dosing before transitioning to regular dosing cycles. Always administer this medicine under the supervision of a qualified clinician in accordance with approved prescribing guidelines.

• Treatment with Epkinly/Tepkinly can cause Cytokine Release Syndrome, a serious reaction that develops when the immune system becomes extremely activated. Symptoms may include chills, fever, low blood pressure, difficulty breathing, or fatigue. Patients must be monitored during treatment, particularly in the initial doses.
• This medicine may cause neurological side effects known as Immune Effector Cell-Associated Neurotoxicity Syndrome. Patients may experience headache, dizziness, confusion, speech difficulties, tremors, or seizures. Immediate medical attention and careful neurological monitoring are important in case symptoms occur during therapy.
• This drug can weaken the immune system and increase the risk of infections, including serious bacterial, viral, or fungal infections. Patients should report symptoms such as chills, fever, cough, or sore throat quickly so appropriate evaluation and treatment can be provided.
• Epkinly/Tepkinly may reduce the blood cell counts, including red blood cells, white blood cells, or platelets. These conditions may increase the probability of infections, fatigue, or bleeding. Regular blood tests are required to monitor blood counts throughout treatment.
• This therapy may cause harm to an unborn baby if administered during pregnancy. Women of childbearing potential should use effective contraception during treatment and for a recommended period after the final dose. Patients should let their healthcare provider know if they become pregnant.
• It is not known whether Epkinly/Tepkinly passes into human breast milk. Because of the potential risk to a breastfed infant, breastfeeding is generally not required during treatment and for a period after the final dose. Patients should consult their clinician.

What documents are required to import EPKINLY/TEPKINLY to India?

EPKINLY/TEPKINLY (epcoritamab-bysp) injection can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is EPKINLY/TEPKINLY available in India?

EPKINLY/TEPKINLY (epcoritamab-bysp injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) facilitates the import of cancer medicines under named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On the availability of Epkinly/Tepkinly in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Epkinly/Tepkinly price in India.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

EPKINLY/TEPKINLY can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of EPKINLY/TEPKINLY (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91 98104 69557 | Toll-Free Number: 1800-1200-365 or write us at info@indianpharmanetwork.in for Epkinly/Tepkinly cost in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source EPKINLY/TEPKINLY (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Epkinly/Tepkinly®?

Epcoritamab-bysp is the Generic Name for the trade name drug Epkinly/Tepkinly®.

Are Epkinly and Tepkinly the same drug, and what is the difference between these two brand names of epcoritamab?

Epkinly and Tepkinly are the same drug, epcoritamab, a bispecific antibody. Both are used to treat certain B-cell lymphomas. The difference is only in the brand name based on region: Epkinly is approved in the U.S. and Japan, while Tepkinly is approved in the European Union (EU).

What is the Manufacturer’s Name of Epkinly/Tepkinly®?

Epkinly/Tepkinly® is manufactured by Genmab US, Inc.

Is Epkinly approved by the FDA?

Yes. Epkinly is approved by the FDA. Date of first approval: May 19, 2023.

What is the dosage and form of Epkinly/Tepkinly® supplied?

Epkinly/Tepkinly is supplied for Injection: 4 mg/0.8 mL and 48 mg/0.8 mL in a single-dose vial for subcutaneous (SC) use.

What are the most common side effects of Epkinly/Tepkinly® injection?

The most commonly reported side effects of Epkinly/Tepkinly® are CRS, injection site reactions, fatigue, musculoskeletal pain, fever, diarrhea, COVID-19, rash, abdominal pain, upper respiratory tract infections, constipation, and pneumonia.

How does Epkinly/Tepkinly Import in India work?

Epkinly/Tepkinly Import in India is possible through the Named Patient Program. This means the medicine can be imported for a specific patient with a valid doctor’s prescription. Indian Pharma Network helps manage the complete process, including approvals and delivery, making sure the medicine reaches the patient safely and legally.

Who is a reliable Epkinly/Tepkinly supplier in India?

Indian Pharma Network is a trusted Epkinly/Tepkinly supplier in India, facilitating compliant access through global sourcing channels and structured documentation support for eligible patients under applicable regulatory provisions.

How much does Epkinly/Tepkinly® injection cost in India?

Epkinly® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Epkinly prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Epkinly/Tepkinly cost in India, please call/WhatsApp +91 98104 69557 or send an email to info@indianpharmanetwork.in.

Can Epkinly/Tepkinly® injection be available in SAARC countries?

Apart from Gulf countries, Epkinly/Tepkinly® injection can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Epkinly/Tepkinly® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Epkinly/Tepkinly® injection online in India?

Yes, one can buy Epkinly/Tepkinly in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the supply of Epkinly® injection through legal channels.

Who is an authorized Epkinly/Tepkinly importer in India?

Indian Pharma Network acts as an Epkinly/Tepkinly importer in India, assisting with Named Patient import processes, regulatory documentation, and compliant international procurement for patients requiring this therapy.

What are the storage conditions of Epkinly/Tepkinly® injection?

Store refrigerated at 2°C to 8°C (36°F to 46°F). Keep the medicine in the original carton to protect it from light. It is not advisable to freeze or shake the vials.